Capturing incarceration in the medical record: we cannot manage what we cannot measure Justin Berk , Anna Maria South , Farah Acher Kaiksow , Lawrence A Haber Author Notes Health Affairs Scholar, Volume 4, Issue 6, June 2026, qxag101,

https://academic.oup.com/healthaffairsscholar/article/4/6/qxag101/8664602?login=false

Reforming Medicare Payment for Skin Substitutes — Ripping Off the Bandage Jad F Zeitouni, MPH , Xiaodan Hu, PhD MA , Sanket S Dhruva, MD MHS , Joseph S Ross, MD MHS , Vinay K Rathi, MD MBA Health Affairs Scholar, qxag164, https://doi.org/10.1093/haschl/qxag164

https://academic.oup.com/healthaffairsscholar/advance-article/doi/10.1093/haschl/qxag164/8715896?rss=1&login=false

Wage Gaps Between US Nurses With and Without Disabilities Laurin Bixby, PhD, MA , K Jane Muir, PhD, MSHP, RN , Michelle Kephart, MSN, RN , Mihir Kakara, MD, MSHP Health Affairs Scholar, qxag161, https://doi.org/10.1093/haschl/qxag161

https://academic.oup.com/healthaffairsscholar/advance-article/doi/10.1093/haschl/qxag161/8719580?rss=1&login=false

Commercial Prices Relative to Medicare Were Lower Under An Employer-Based Reference Pricing Program Roslyn C Murray, PhD , Christopher M Whaley, PhD Health Affairs Scholar, qxag156, https://doi.org/10.1093/haschl/qxag156

https://academic.oup.com/healthaffairsscholar/advance-article/doi/10.1093/haschl/qxag156/8719573?rss=1&login=false

Fake Cancer Medicines Have Reached US Clinics And Most Providers Don’t Know It Jean Christophe Rusatira,Jean Berchmans Uwimana,Saifuddin Ahmed,andHenry J. Michtalik June 24, 2026

https://www.healthaffairs.org/content/forefront/don-t-fake-cancer-medicines-have-reached-us-clinics-and-most-providers-know?utm_campaign=forefront&utm_medium=email&_hsenc=p2ANqtz-8sEzAnVLLsXTAyoKZpmIIMHO5sllD3A6mLVfYUzgl8pBeASnObPtIqCGRBnVjEiZFQm7JUayOmNKOXuK8dq5uG2ARmFA&_hsmi=425789085&utm_source=hasu Providers in high-income countries underestimate the domestic scale of falsified medicine.

How Foreign Reference Pricing Embeds Valuations And Risks Undermining Global Innovation Jason Shafrin,Richard Xie,andLouis P. Garrison, Jr. June 24, 2026

https://www.healthaffairs.org/content/forefront/import-price-import-threshold-foreign-reference-pricing-embeds-valuations-and-risks?utm_campaign=34032557-Health%20Affairs%20Sunday%20Update%202026&utm_medium=email&_hsenc=p2ANqtz-_issIK9IBjfLeM6_erjx6IbEK5fbSJmXCXKsFMObZ58Dl1h5EM4wupXdxbqDgKUInyxMHWjSlgt8I7oyaS6nSRtxTXCg&_hsmi=425789085&utm_content=425789085&utm_source=hs_email Foreign reference pricing frameworks often differ from the way the US has historically valued medical innovation. A more sustainable approach would be to define and apply US-specific measures of value and to invest in generating evidence around value.

Massively Better, By What Measure? Soleil Shah June 26, 2026

https://www.healthaffairs.org/content/forefront/massively-better-measure?utm_campaign=forefront&utm_medium=email&_hsenc=p2ANqtz-8aGg1je1tRQMuR30qg-PzP8_DYJvaaQQFVOzkQw3ITv5ikL_8m_Lg6K0-IuZFypvV1ze5TZpYBnwDGXN92LWDZVY_WSw&_hsmi=425789085&utm_source=hasu Perhaps the term “better” should not be defined by business metrics at all—but instead by the innovation’s health impacts among patients.